Novel Soluable Gamma-Secretase Modulators

Funding year(s): 
2010
Funding to date: 
$250,000

Building on in vitro characterization of a novel series of soluable gamma-secretase modulators (SGSMs) funded by Cure Alzheimer’s Fund, the current project is a thorough pharmacological or in vivo examination of these molecules to identify the best or “lead” drug candidate.

Researchers

Headshot photo
Steve Wagner, Ph.D.

Principal Investigator, Department of Neurosciences, School of Medicine, University of California, San Diego

Headshot photo
Rudy Tanzi, Ph.D.

Dr. Rudolph Tanzi serves as Chair of the Cure Alzheimer’s Fund Research Consortium. He is also the Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard University and Director of the Genetics and Aging Research Unit at Massachusetts General Hospital (MGH).